Jul 26, 2021 12:38 PM IST
Sold under the brand name Alzumab, itolizumab has been used in treatment of psoriasis treatment since 2013.
- Jul 26, 2021 09:33 AM IST
- Jul 23, 2021 10:52 AM IST
- Jul 23, 2021 10:50 AM IST
- Jul 13, 2021 10:55 AM IST
Insider trading cases are hard to prove but regulators don’t stop trying to stamp out this menace. In Biocon’s case, Sebi’s orders raise vital questions on their soundness.
- Jul 12, 2021 07:35 PM IST
Net Sales are expected to increase by 13.4 percent Y-o-Y (up 3.1 percent Q-o-Q) to Rs 1,895.3 crore, according to ICICI Direct.
- Jul 09, 2021 09:08 PM IST
Mazumdar-Shaw's tweet came after Sebi barred Allegro Capital and one of its senior executives from the securities market for one year in a case related to alleged insider trading activities in the shares of Biocon.
- Jul 06, 2021 01:38 PM IST
Global research firm CLSA has maintained sell on the stock with target at Rs 260 per share. It is of the view that cash flow remained negative for an eighth consecutive year in FY21 with operating cash flow falling 24 percent YoY and capex intensity remaining high.
- Jul 01, 2021 11:39 AM IST
Biocon had announced information relating to its collaboration with Sandoz and the period of unpublished price sensitive information (UPSI) was from December 20, 2017 to January 18, 2018, The Securities and Exchange Board of India (Sebi) noted in an order passed late on Wednesday.
- Jun 15, 2021 12:03 PM IST
Kiran Mazumdar-Shaw, 68, is one of the key speakers at the 15th edition of the annual virtual summit on June 22 hosted by the USA India Chambers of Commerce.
- May 25, 2021 03:05 PM IST
ICICI Direct recommended hold rating on Biocon with a target price of Rs 400 in its research report dated April 29, 2021.
- May 15, 2021 06:09 PM IST
Earlier this week, Mazumdar-Shaw had expressed concern over shortage of COVID-19 vaccines and sought better transparency from the government regarding their availability so that citizens could patiently wait for their turn.
- May 03, 2021 02:46 PM IST
The sharp surge in COVID-19 cases across has created a massive demand and consequent shortage of medical oxygen and essential drugs.
- May 03, 2021 11:06 AM IST
There is a perceptible change in the Laurus Labs' management commentary in the last 18 months that points to growth sustenance for the medium term
- Apr 29, 2021 12:03 PM IST
- Apr 29, 2021 11:24 AM IST
- Apr 19, 2021 12:23 PM IST
Biocon Executive Chairperson Kiran Mazumdar Shaw says scarcity of critical anti-COVID-19 drugs Remdesivir and Itolizumab will end in 4-6 weeks as suppliers like her own company ramp up output that fell when the pandemic was receding. She said market pricing of vaccines is a must for the much-needed acceleration in inoculation.
- Apr 18, 2021 06:26 PM IST
The CRAMs ( contract research and manufacturing services) segment is fetching rich valuations globally and back home, the segment has seen minority stake sale deals like True North-Anthem Biosciences & TPG-Sai Lifesciences.
- Apr 12, 2021 08:40 PM IST
Net Sales are expected to increase by 28.3 percent Y-o-Y (up 8 percent Q-o-Q) to Rs. 1,999.6 crore, according to Sharekhan.
- Apr 12, 2021 10:58 AM IST
"Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received a certificate of Good Manufacturing Practice (GMP) compliance from the Medicines and Healthcare products Regulatory Agency (MHRA), the United Kingdom (UK), for its manufacturing facility at Biocon Park in Bengaluru," Biocon said in a regulatory filing.
- Apr 12, 2021 10:25 AM IST
Multi-year opportunity awaits Indian vaccine manufacturers such as DRL, Gland Pharma, Aurobindo Pharma and Cadila Pharma
- Feb 12, 2021 11:13 AM IST
This follows the positive recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency, a Biocon statement said on Friday.
- Feb 02, 2021 09:11 PM IST
Motilal Oswal recommended Neutral rating on Biocon with a target price of Rs 385 in its research report dated January 22, 2021.
- Feb 01, 2021 06:36 PM IST
Sharekhan is bullish on Biocon has recommended buy rating on the stock with a target price of Rs 470 in its research report dated January 22, 2021.
- Jan 28, 2021 02:58 PM IST
ICICI Direct recommended hold rating on Biocon with a target price of Rs 450 in its research report dated January 22, 2021.